TG and hypothyroidism: Miyake et al. reported in a prospective observational trial that 23.9 % of patients with metastatic Renal Cell Carcinoma receiving sorafenib had decreased TSH levels before developing hypothyroidism, which suggested a drug-induced destructive thyroiditis causing thyroid hormone release [5].